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Epidemiology and Prevention
Subclinical Thyroid Dysfunction and the Risk of Heart
Failure Events
An Individual Participant Data Analysis From 6 Prospective Cohorts
Baris Gencer, MD; Tinh-Hai Collet, MD; Vanessa Virgini, MD; Douglas C. Bauer, MD;
Jacobijn Gussekloo, MD, PhD; Anne R. Cappola, MD, ScM; David Nanchen, MD;
Wendy P.J. den Elzen, PhD; Philippe Balmer, BSc; Robert N. Luben, PhD; Massimo Iacoviello, MD;
Vincenzo Triggiani, MD; Jacques Cornuz, MD, MPH; Anne B. Newman, MD, MPH;
Kay-Tee Khaw, MD; J. Wouter Jukema, MD, PhD; Rudi G.J. Westendorp, MD, PhD;
Eric Vittinghoff, PhD; Drahomir Aujesky, MD, MSc; Nicolas Rodondi, MD, MAS;
for the Thyroid Studies Collaboration
Background—American College of Cardiology/American Heart Association guidelines for the diagnosis and management
of heart failure recommend investigating exacerbating conditions such as thyroid dysfunction, but without specifying the
impact of different thyroid-stimulation hormone (TSH) levels. Limited prospective data exist on the association between
subclinical thyroid dysfunction and heart failure events.
Methods and Results—We performed a pooled analysis of individual participant data using all available prospective
cohorts with thyroid function tests and subsequent follow-up of heart failure events. Individual data on 25 390
participants with 216 248 person-years of follow-up were supplied from 6 prospective cohorts in the United States and
Europe. Euthyroidism was defined as TSH of 0.45 to 4.49 mIU/L, subclinical hypothyroidism as TSH of 4.5 to 19.9
mIU/L, and subclinical hyperthyroidism as TSH 0.45 mIU/L, the last two with normal free thyroxine levels. Among
25 390 participants, 2068 (8.1%) had subclinical hypothyroidism and 648 (2.6%) had subclinical hyperthyroidism. In
age- and sex-adjusted analyses, risks of heart failure events were increased with both higher and lower TSH levels (P
for quadratic pattern 0.01); the hazard ratio was 1.01 (95% confidence interval, 0.81–1.26) for TSH of 4.5 to 6.9
mIU/L, 1.65 (95% confidence interval, 0.84–3.23) for TSH of 7.0 to 9.9 mIU/L, 1.86 (95% confidence interval,
1.27–2.72) for TSH of 10.0 to 19.9 mIU/L (P for trend 0.01) and 1.31 (95% confidence interval, 0.88–1.95) for TSH
of 0.10 to 0.44 mIU/L and 1.94 (95% confidence interval, 1.01–3.72) for TSH 0.10 mIU/L (P for trend0.047). Risks
remained similar after adjustment for cardiovascular risk factors.
Conclusion—Risks of heart failure events were increased with both higher and lower TSH levels, particularly for TSH 10
and 0.10 mIU/L. (Circulation. 2012;126:1040-1049.)
Key Words: cohort studies  epidemiology  heart failure  meta-analysis  thyroid
Heart failure (HF) is a frequent cause of hospitalizationin people 65 years of age, with an increasing trend
in the number of patients living with HF.1,2 Given that
HF constitutes a major public health problem within the
context of an aging and growing population,1,3–5 recogniz-
ing modifiable risk factors for HF events is essential to
target subjects who are at risk for developing this condi-
tion.6,7 The American College of Cardiology/American
Heart Association guidelines for the diagnosis and manage-
ment of HF in adults recommend measurement of thyroid
function to investigate conditions that might exacerbate HF
such as hypothyroidism or hyperthyroidism but without
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specifying the potential impact of different thyroid-stimulating
hormone (TSH) levels.8
Clinical Perspective on p 1049
Subclinical thyroid dysfunction is common, particularly in
older individuals, with a prevalence of subclinical hypothy-
roidism up to 10% and of subclinical hyperthyroidism be-
tween 0.7% and 3.2%.9 Subclinical hypothyroidism is defined
as a serum TSH concentration above the upper limit of the
reference range with serum free thyroxine (FT4) concentra-
tion within its reference range. Subclinical hyperthyroidism is
defined as a serum TSH concentration below the lower limit
of the reference range with serum FT4 and free triiodothyro-
nine (FT3) concentrations within their reference ranges.10,11
Subclinical hypothyroidism and subclinical hyperthyroidism
have been associated with an increased risk of coronary heart
disease events and mortality,12–14 but few prospective data are
available concerning the association of subclinical thyroid
dysfunction and the risk of HF events, and the strengths of
associations varied.15–18 Subclinical thyroid dysfunction has
been associated with systolic and diastolic cardiac dysfunc-
tion.16,19 Small studies have shown that thyroxine replace-
ment improved measurements of cardiac function in subjects
with subclinical hypothyroidism.20 However, no randomized,
controlled trials have been performed to evaluate the therapy
effect among individuals with subclinical thyroid dysfunction
with clinical HF outcomes. Currently, the evidence for screening
and treating subclinical thyroid dysfunction is limited.10,21,22
To clarify the association between subclinical thyroid
dysfunction and HF events, we performed a pooled analysis
of individual participant data using all available prospective
cohorts. Analysis of individual participant data from large
cohort studies may reconcile heterogeneity between studies
by allowing a common TSH cutoff for subclinical thyroid
dysfunction and further adjustment of similar confounding
factors. Individual participant data analysis is the best method
for assessing the impact of the degree of subclinical thyroid
dysfunction (measured by TSH level) and of preexisting HF
or cardiovascular disease (CVD) in subgroup analyses and




We updated our previous systematic review13 of articles in any
language published from 1950 to June 30, 2011, in the MEDLINE
and EMBASE databases on the association between subclinical
thyroid dysfunction and cardiovascular outcomes, searched bibliog-
raphies for key articles, and contacted experts in this field (see
Methods in the online-only Data Supplement). For this analysis, we
followed predefined inclusion criteria considering only full-text,
published longitudinal cohort studies that fulfilled the following
conditions: (1) measurement of TSH and FT4 levels at baseline in
adults, (2) systematic follow-up over time, (3) assessment of HF
events, and (4) a control euthyroid group. We excluded studies that
considered only persons taking thyroid medications (antithyroid drug
or thyroxine replacement) or those with overt thyroid dysfunction
(defined by abnormal TSH and FT4 levels). The updated search for
additional studies until June 30, 2011, was independently assessed by
2 authors (B.G. and P.B.); any discrepancy between the authors was
resolved by discussion with a third author (N.R.). The agreement rate
between the 2 reviewers was 99.9% for the first screen (titles and
abstracts; 0.66; 95% confidence interval [CI], 0.62–0.72) and
100% for the full-text screen (1.00). The assessment of the
methodological quality of included studies was performed according
to previously described criteria.14 Two authors (N.R. and J.G.) rated
all studies for quality: methods of outcome adjudication, evaluation
of confounders, and completeness of follow-up. All studies were
approved by institutional review boards, and all participants gave
written informed consent.
Investigators from eligible studies were contacted to join the Thyroid
Studies Collaboration. We requested data about the baseline thyroid
function (TSH and FT4, FT3 if available), HF outcome data, demo-
graphic characteristics (age, sex, race), cardiovascular risk factors (total
cholesterol, diabetes mellitus, blood pressure, cigarette smoking), pre-
existing CVD, preexisting HF, medication (lipid-lowering drugs, anti-
hypertensive drugs, thyroxine replacement, and antithyroid medication),
and other potential confounding variables for HF such as body mass
index, creatinine, and atrial fibrillation (AF).
Definition of Subclinical Thyroid Dysfunction
To maximize the comparability of the studies, we used a common
definition of subclinical thyroid dysfunction based on expert re-
views,10,21 the definition used in the Cardiovascular Health Study,16,25
and a consensus meeting of our collaboration (International Thyroid
Conference, Paris, 2010). Euthyroidism was defined as a TSH level of
0.45 to 4.49 mIU/L, subclinical hypothyroidism as a TSH level of 4.5 to
19.9 mIU/L, and subclinical hyperthyroidism as a TSH level 0.45
mIU/L, the last two with normal FT4 levels. On the basis of previously
described TSH cutoffs13,16 and expert reviews,10,21 subclinical hypothy-
roidism was subdivided into 3 groups: TSH of 4.5 to 6.9, 7.0 to 9.9, and
10.0 to 19.9 mIU/L; subclinical hyperthyroidism was subdivided into 2
groups: TSH of 0.10 to 0.44 and 0.10 mIU/L. For FT4, we used
study-specific cutoffs (Table I in the online-only Data Supplement)13
because FT4 measurements show greater intermethod variation than
TSH assays. As done in a previous study,13 participants with missing
FT4 values were included in the primary analyses and excluded in the
sensitivity analyses because the vast majority of adults with an abnormal
TSH have subclinical and not overt thyroid dysfunction.26 FT3 was
measured in 2 studies (Table I in the online-only Data Supplement)17,27
and was added to the definition of subclinical hyperthyroidism in
sensitivity analyses. As done in previous studies,12,13,15,27 we performed
sensitivity analyses excluding participants using thyroid medication
(thyroxine, antithyroid drug) at baseline and during follow-up.
Definition of HF Events
To limit outcome heterogeneity, HF events were defined by any
acute HF events diagnosed by a physician, hospitalization, and
deaths related to HF events on the basis of all available documents
(symptoms, signs, therapy, chest radiographs) within each cohort
(Table I in the online-only Data Supplement). The blindness of HF
outcomes assessment to baseline thyroid status was evaluated in each
cohort, and sensitivity analyses were performed according to HF
outcomes adjudication process by experts. Participants with preex-
isting HF were included in the primary analyses, as performed in our
previous individual participant data analysis evaluating coronary
heart disease outcome,12,13 and were separately analyzed in stratified
analyses to explore the association between subclinical thyroid
dysfunction and incident HF events and recurrent HF events.
Potential Confounders
Primary analyses were adjusted for age and sex and then for
traditional cardiovascular risk factors (systolic blood pressure, total
cholesterol, smoking status, diabetes mellitus) that were available in
all cohorts. We further adjusted the multivariable models for other
potential confounding factors such as creatinine, body mass index,
preexisting AF at baseline, and cardiovascular medications (lipid-
lowering and antihypertensive treatment).
To explore heterogeneity, we performed predefined stratified
analyses according to age, sex, race, TSH levels, preexisting CVD,
and preexisting HF. We also performed sensitivity analyses exclud-
ing participants with AF at baseline, a common cause of HF events.
Gencer et al Thyroid Dysfunction and Heart Failure 1041
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Statistical Analyses
For statistical analyses, we performed 2-stage individual participant
data analyses as recommended24,28 and used in a recent publica-
tion.12,13 Briefly, we performed separate Cox proportional hazards
models to assess the association of subclinical thyroid dysfunction
with HF events for each cohort (SAS 9.2, SAS Institute Inc, Cary,
NC; Stata 12.1, StataCorp, College Station, TX). The pooled
estimates were calculated from random-effects models based on
inverse variance model and summarized with forest plots (Review
Manager 5.1.2, Nordic Cochrane Centre, Copenhagen, Denmark).
We tested for linear trend across TSH and age categories and for
interaction according to sex, race, preexisting CVD, and preexisting
HF. In post hoc analysis, we also tested for quadratic patterns across
TSH categories. All tests were 2 sided. We did not perform formal
adjustments for multiple comparisons, which can be conservative for
correlated outcomes. However, we recognize the potential for
inflation of the type I error rate and interpret nominally significant
(P0.05) results cautiously and in context. To assess heterogeneity
across studies, we used the I2 statistic, estimating the proportion of
the variance across studies attributed to heterogeneity rather than
chance.29 The proportional hazard assumption was assessed with
graphical methods and Schoenfeld tests (all P0.05). We used age-
and sex-adjusted funnel plots to assess for publication bias and the
Egger test.30 In some subgroups analyses, some strata had partici-
pants with no HF events, and we used penalized likelihood methods
to obtain hazard ratios (HRs) and 95% CIs,31 as in our previous
individual participant data analyses.12,13
Results
Among 5413 identified publications, 6 prospective studies
met eligibility criteria and reported HF events (Figure I in the
online-only Data Supplement); all agreed to provide individ-
ual participant data (Table 1). The final sample consisted of
25 390 participants: 22 674 were euthyroid (89.3%), 2068
had subclinical hypothyroidism (8.1%), and 648 had subclin-
ical hyperthyroidism (2.6%). The median follow-up was 10.4
years, with a total follow-up of 216 248 person-years. During
follow-up, 2069 participants had HF events. The quality
assessment of these studies showed that all studies had a loss
of follow-up of 5%, and all outcome adjudicators were
blinded for thyroid status. A formal adjudication was done in
3 studies15,16,18; the other cohorts relied on hospital dis-
charge17,32 or general practitioners’ medical records27 (Table
I in the online-only Data Supplement).
In age- and sex-adjusted analyses, the risk of HF increased
in participants with both higher and lower TSH levels (the
Figure) with a significant test for parabolic function across
TSH categories (P for quadratic pattern 0.01). For subclin-
ical hypothyroidism compared with euthyroidism, the HR
was 1.01 (95% CI, 0.81–1.26) for TSH of 4.5 to 6.9 mIU/L,
1.65 (95% CI, 0.84–3.23) for TSH of 7.0 to 9.9 mIU/L, and
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13 066 58 (40–78) 7104 (54.4) 720 (5.5) 360 (2.8) 0 (0.0) NA 0 (0.0) 1995–1998 11.4 (10.7–12.3) 143 694
Leiden
85-Plus Study
All adults 85 y of
age living in Leiden,
the Netherlands
514 85 336 (65.4) 35 (6.8) 23 (4.5) 17 (3.3) 20 (3.9) 26 (5.1) 1997–1999 4.8 (2.0–5.0) 1861

















5649 75 (69–83) 2884 (51.0) 444 (7.9) 133 (2.3) 207 (3.7) NA 207 (3.7) 1997–1999 3.3 (3.0–3.5) 17 923
Overall 6 Studies 25 390 70 (21–100) 13 648 (53.8) 2068 (8.1) 648 (2.6) 513 (2.0) 622 (2.4) 844 (3.3) 1989–2008 10.4 (3.7–12.0) 216 248
Q1 indicates first quartile; Q3, third quartile; and HF, heart failure.
*We used a common definition of subclinical hypothyroidism and hyperthyroidism, whereas TSH cutoff values varied among the previous reports from each cohort,
resulting in different numbers of subclinical hypothyroidism and hyperthyroidism from previous reports.
†Data on thyroid medication use were not available for 1 participant in the Cardiovascular Health Study and 8 participants in the Health, Aging and Body Composition
Study at baseline and for all participants during follow-up in European Prospective Investigation of Cancer–Norfolk.
‡For all cohorts, we used the maximal follow-up data that were available, which might differ from previous reports for some cohorts.
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1.86 (95% CI, 1.27–2.72) for TSH of 10.0 to 19.9 mIU/L (P
for trend across higher TSH categories 0.01). For subclin-
ical hyperthyroidism compared with euthyroidism, the HR
was 1.31 (95% CI, 0.88–1.95) for TSH of 0.1 to 0.44 mIU/L
and 1.94 (95% CI, 1.01–3.72) for TSH 0.10 mIU/L (P for
trend across lower TSH categories0.047).
Among all participants with subclinical hypothyroidism
(Table 2), the HR for HF events was 1.26 (95% CI, 0.91–
1.74) in age- and sex-adjusted analyses with heterogeneity
(I277%) across studies (Figure II in the online-only Data
Supplement). The risk seemed to be higher in younger
participants, but the number of events was small and therefore
results were possibly not significant. Among older partici-
pants (80 years of age), HF events were not increased, and
the interaction test across age categories was not significant
(P0.10). We found slightly higher risks in men and whites
but without significant interaction test (P0.10), as well as
for preexisting CVD or preexisting HF. Risks were similar
after further adjustment for cardiovascular risk factors, al-
though the strength of the association was attenuated, with the
HR remaining significant among those with TSH levels
10.0 mIU/L (HR, 1.59; 95% CI, 1.15–2.19). Sensitivity
analyses (Table 3) yielded similar results. After the exclusion
of participants using thyroid medication at baseline and
during follow-up, the association was stronger among those
with TSH between 10.0 and 19.9 mIU/L (HR, 2.37; 95% CI,
1.59–3.54). Risks remained elevated among those with TSH
10.0 mIU/L after the exclusion of those with missing FT4
values, after further adjustment for additional HF risk factors
(creatinine, body mass index, and preexisting AF), and after
exclusion of those with preexisting AF. After exclusion of the
Bari study (all with preexisting HF),17 the HR decreased to
1.62 (95% CI, 1.15–2.29) with a low heterogeneity (I20%).29
Risks were lower after the analyses were limited to cohorts with
formal adjudication procedures by experts; this analysis was
possible for only 3 studies of older adults (Table I in the
online-only Data Supplement).
Among all participants with subclinical hyperthyroidism
(Table 4), the HR for HF events in age- and sex-adjusted
analyses was 1.46 (95% CI, 0.94–2.27) compared with
euthyroidism with heterogeneity (I261%) across studies
(Figure III in the online-only Data Supplement). In contrast to
subclinical hypothyroidism, the risk was significantly in-
creased among participants 80 years of age (HR, 2.34; 95%
CI, 1.27–4.31), but there was not a significant trend across
age categories (P0.98). We found higher risks among
women and whites, but the interaction test was not significant
(P0.30), and for preexisting CVD or preexisting HF. Risks
were similar after further adjustment for cardiovascular risk
factors.
Among participants with TSH 0.10 mIU/L, the HR for
HF events was 1.94 (95% CI, 1.01–3.72) in age- and
sex-adjusted analyses. In sensitivity analyses (Table II in the
online-only Data Supplement), with those using thyroid
medication at baseline excluded, the HR was 1.80 mIU/L
(95% CI, 1.04–3.13). Risks were similar after further adjust-
ments for HF potential confounding risk factors (body mass
index, creatinine, and AF), after the exclusion of those with
missing FT4 or abnormal FT3, and after the exclusion of
those with preexisting HF or preexisting AF.
We found limited evidence of publication bias with visual
assessment of age- and sex-adjusted funnel plots, although
the Bari study might be an outlier with no corresponding
negative study of similar size, and with the Egger test for
subclinical hypothyroidism (P0.23) and subclinical hyper-
thyroidism (P0.60), although such analyses were limited by
the small number of included studies.
Discussion
In this individual data analysis of 25 390 participants from 6
prospective cohorts, risks of HF events were increased with
higher and lower TSH levels than TSH levels in the normal
range, with statistically significant increased risks among
those with TSH 10.0 mIU/L (HR, 1.86; 95% CI, 1.27–2.72)
and those with TSH 0.10 mIU/L (HR, 1.94; 95% CI,
1.01–3.72). The HF risks were explained mainly by the
degree of thyroid dysfunction, with an observed parabolic
Figure. Hazard ratios (HRs) for heart failure (HF) events according to thyroid-stimulating hormone (TSH) levels. Age- and sex-adjusted
HRs and their 95% confidence intervals (CIs) are represented by squares. Squares to the right of the solid lines indicate increased risk
of HF events. Sizes of data markers are proportional to the inverse of the variance of the HRs.
Gencer et al Thyroid Dysfunction and Heart Failure 1043
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association between TSH levels and risk of HF events (P
for quadratic pattern 0.01). The increased risk of HF in
adults for TSH 10.0 mIU/L persisted after the exclusion
of those with preexisting HF or preexisting AF. Further
adjustment for cardiovascular risk factors and other avail-
able HF confounding risk factors did not significantly
change the association with HF events, although part of the
risk seemed to be mediated by cardiovascular risk factors
because point estimates were decreased in multivariate
models. Excluding participants using thyroid medications
(mainly thyroxine replacement) at baseline and during
follow-up further increased the risks.









Multivariate Model*Events Participants Events Participants
Total population 1762 22 674 250 2068 1.26 (0.91–1.74) 1.22 (0.93–1.59)
Sex†
Male 977 10 793 120 730 1.33 (0.91–1.94) 1.28 (0.93–1.76)
Female 785 11 881 130 1338 1.03 (0.85–1.24) 1.07 (0.84–1.36)
P for interaction 0.24 0.38
Age, y‡
18–49§ 15 2756 2 107 4.56 (0.57–36.30) 5.52 (0.66–46.25)
50–64 128 5798 10 373 1.39 (0.62–3.08) 1.79 (0.47–6.80)
65–79 1370 12 666 205 1428 1.31 (0.92–1.87) 1.30 (0.93–1.82)
80 249 1454 33 160 1.01 (0.69–1.46) 0.98 (0.66–1.44)
P for trend 0.16 0.10
Race
White 1573 21 541 230 1960 1.30 (0.92–1.82) 1.25 (0.93–1.67)
Black 189 1133 20 108 1.04 (0.66–1.67) 1.03 (0.64–1.67)
P for interaction 0.44 0.50
TSH, mIU/L
0.45–4.49 1762 22 674 1 (Referent) 1 (Referent)
4.5–6.9 156 1422 1.01 (0.81–1.26) 1.01 (0.81–1.25)
7.0–9.9 54 422 1.65 (0.84–3.23) 1.78 (0.94–3.38)
10.0–19.9 40 224 1.86 (1.27–2.72) 1.59 (1.15–2.19)
P for trend 0.01 0.01
Preexisting CVD¶
None 1091 18 448 162 1611 1.36 (0.93–2.01) 1.33 (0.96–1.84)
Yes 669 4214 88 456 1.19 (0.77–1.85) 1.16 (0.77–1.76)
P for interaction 0.65 0.61
Preexisting HF#
None 1205 10 247 180 1285 0.95 (0.81–1.11) 0.95 (0.81–1.12)
Yes 132 440 33 63 1.73 (0.81–3.69) 1.66 (0.86–3.23)
P for interaction 0.13 0.11
HF indicates heart failure; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; and CVD, cardiovascular
disease.
*Adjusted for age, sex, systolic blood pressure, current and former smoking, total cholesterol, and prevalent diabetes mellitus at
baseline.
†These HRs were not adjusted for sex.
‡These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
§Bari was excluded from this stratum because of only 1 participant with subclinical hypothyroidism leading to unstable estimates.
The Cardiovascular Health Study (CHS) was excluded from this stratum because of no participants with subclinical hypothyroidism.
¶Data on previous CVD were not available for 11 participants in the European Prospective Investigation of Cancer (EPIC)–Norfolk
and for 2 participants in the Leiden 85-Plus Study.
#No data were available in the EPIC–Norfolk (only preexisting overall CVD assessed); there was 1 missing value in Leiden 85-Plus
Study, and by inclusion criteria, all participants had HF at baseline in Bari study. No participants in the Prospective Study of Pravastatin
in the Elderly at Risk had preexisting HF. The CHS was not included for the multivariable in those with preexisting HF because the
model was unstable (1 event/2 participants).
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To the best of our knowledge, this is the first individual
participant data analysis of large cohorts examining the
association between subclinical thyroid dysfunction and HF
events. Our findings are consistent with previous observa-
tional studies15,16,18 that reported a higher incidence and
recurrent risks of HF among participants with higher TSH
levels compared with euthyroid participants; our individual
participant data analysis assessed this risk across a larger age
range and several subgroups. The Health, Aging, and Body
Composition Study previously reported an increased risk of
HF events among subjects with TSH 7.0 mIU/L (HR, 2.58;
95% CI, 1.19–5.60 for TSH of 7.0–9.9 mIU/L; and HR, 3.26;
95% CI, 1.37–7.77 for TSH 10.0 mIU/L) over a 4-year
follow-up, with a higher risk for recurrent HF events among
those with preexisting HF (HR, 7.62; 95% CI, 2.25–25.77)15;
these data were updated with 8-year follow-up in the present
analysis. The Cardiovascular Health Study16 reported an
increased risk of HF events among subjects with TSH 10.0
Table 3. Sensitivity Analyses of the Effect of Subclinical Hypothyroidism on the Risk of Heart Failure Events
Subclinical Hypothyroidism
Euthyroidism, n TSH 4.5–19.9 mIU/L TSH 10.0–19.9 mIU/L
Events Participants Events, n Participants, n HR (95% CI) Events, n Participants, n HR (95% CI)
All eligible studies
Random-effects model 1762 22 674 250 2068 1.26 (0.91–1.74) 40 224 1.86 (1.27–2.72)
Fixed-effects model 1762 22 674 250 2068 1.10 (0.96–1.26) 40 224 1.81 (1.32–2.49)
Excluding those with thyroid
medication use*
At baseline 1730 22 351 237 1937 1.28 (0.88–1.87) 33 192 1.36 (0.92–1.99)
At baseline and during
follow-up†
1696 22 238 197 1732 1.26 (0.93–1.69) 24 146 2.37 (1.59–3.54)
Excluding those with missing
FT4‡
1762 22 674 208 1575 1.34 (0.93–1.95) 39 220 1.91 (1.26–2.88)
Outcomes
3 Studies with formal
adjudication procedures§
1205 9943 186 1274 0.96 (0.82–1.12) 27 129 1.66 (0.95–2.91)
Further adjustments of
multivariate models
Plus body mass index,
creatinine, and atrial fibrillation
at baseline
1326 10 644 213 1342 1.13 (0.86–1.48) 36 144 1.51 (1.06–2.15)
Plus lipid-lowering and
antihypertensive medications¶
1336 10 681 212 1347 1.14 (0.85–1.53) 35 143 1.55 (1.09–2.19)
Excluding study of cardiac
patients (Bari)
1709 22 385 229 2029 1.04 (0.88–1.22) 33 214 1.62 (1.15–2.29)
Excluding preexisting HF# 1630 22 234 217 2005 1.04 (0.87–1.26) 31 211 1.67 (1.12–2.49)
Excluding baseline atrial
fibrillation**
1698 22 500 238 2043 1.26 (0.92–1.72) 37 220 1.81 (1.27–2.58)
TSH indicates thyroid-stimulating hormone; HR, hazard ratio; CI, confidence interval; FT4, free thyroxine; and HF, heart failure. HRs are all age- and sex-adjusted
unless stated otherwise.
*The numbers of participants with thyroid medication appear in Table 1.
†Leiden was excluded from this stratum because of 0 participants with subclinical hypothyroidism.
‡A total of 493 participants with subclinical hypothyroidism and missing FT4 were excluded: 21 participants excluded from the Cardiovascular Health Study (CHS),
230 from the Health, Aging and Body Composition Study (HABC; FT4 was not measured in HABC when TSH 7.0 mIU/L), 241 from the Prospective Study of Pravastatin
in the Elderly at Risk (PROSPER), and 1 from Leiden 85-Plus Study.
§Formal adjudication procedures with experts adjudicating each case were performed only in CHS, HABC, and PROSPER. See Table I in the online-only Data
Supplement.
Data on creatinine and atrial fibrillation were not available at baseline for the European Prospective Investigation of Cancer (EPIC)–Norfolk study. 50 participants
with missing data for body mass index, creatinine, and atrial fibrillation: 9 in CHS, 24 in HABC, and 17 in Leiden.
¶Data on lipid-lowering and antihypertensive medications were not available for the EPIC-Norfolk study. Eight participants had missing data for hypertensive and
lipid-lowering treatment: 1 in CHS and 7 in HABC.
#A total of 503 were excluded because of HF at baseline: 11 in CHS, 106 in HABC, 58 in Leiden 85-Plus Study (1 missing value), 328 in Bari (all participants with
preexisting HF), and 0 in PROSPER. Data on preexisting HF were not available for EPIC-Norfolk (only preexisting overall CVD assessed); after the exclusion of those
with preexisting CVD from EPIC-Norfolk, the HR was 1.62 (95% CI, 1.02–2.58) for TSH of 10.0 to 19.9 mIU/L.
**A total of 199 participants were excluded because of AF at baseline: 58 in CHS, 49 in HABC, 45 in Leiden 85-Plus Study, and 43 in Bari. Data were not available for
EPIC-Norfolk. Baseline AF was an exclusion criteria from PROSPER trial (4 participants had AF at baseline); 1 was missing in HABC and 2 were missing in Leiden. After exclusion
of EPIC-Norfolk, the HR was 1.92 (95% CI, 1.24–2.96) for TSH of 10.0 to 19.9 mIU/L. Prevalence of baseline AF across TSH categories: 170 of 5615 (3.0%) for TSH of 0.45
to 4.49 mIU/L, 20 of 628 (3.2%) for TSH of 4.5 to 6.9 mIU/L, 1 of 174 (0.6%) for TSH of 7.0 to 9.9 mIU/L, and 4 of 102 (3.9%) for TSH of 10.0 to 19.9 mIU/L.
Gencer et al Thyroid Dysfunction and Heart Failure 1045
 at Rijksuniversiteit Leiden on March 18, 2013http://circ.ahajournals.org/Downloaded from 
mIU/L (HR, 1.88; 95% CI, 1.05–3.34) over a 12-year
follow-up; these data were updated with 14-year follow-up in
the present analysis. The Prospective Study of Pravastatin in
the Elderly at Risk (PROSPER) study18 recently reported an
increased risk of HF hospitalization among subjects with
TSH 10.0 mIU/L (HR, 3.01; 95% CI, 1.12–8.11) and
among those with suppressed TSH 0.10 mIU/L (HR, 4.61;
95% CI, 1.71–12.47). The Bari study, which examined only
patients with preexisting HF,17 reported an increased risk of
recurrent HF events among participants with subclinical
hypothyroidism (HR, 2.03; 95% CI, 1.16–3.55) but without a
categorization of TSH levels. We previously found a similar
pattern with an increased risk of coronary heart disease
mortality among participants with subclinical hypothyroidism
and subclinical hyperthyroidism, particularly in those with
more severe thyroid dysfunction.12,13 The present data and









Multivariate Model*Events Participants Events Participants
Total population 1762 22 674 57 648 1.46 (0.94–2.27) 1.51 (0.93–2.44)
Sex†
Male 977 10 793 20 219 1.22 (0.77–1.94) 1.21 (0.77–1.89)
Female 785 11 881 37 429 1.72 (1.02–2.91) 1.56 (0.97–2.50)
P for interaction 0.33 0.45
Age, y‡
18–49§ 15 2756 0 71 1.95 (0.10–39.59) 2.61 (0.14–49.09)
50–64 128 5798 4 151 1.79 (0.26–12.34) 1.63 (0.26–10.02)
65–79 1370 12 666 37 375 1.20 (0.82–1.77) 1.20 (0.81–1.76)
80 249 1454 16 51 2.34 (1.27–4.31) 2.40 (1.19–4.85)
P for trend 0.98 0.91
Race
White 1573 21 541 52 615 1.49 (0.95–2.35) 1.50 (0.95–2.35)
Black 189 1133 5 33 1.07 (0.46–2.51) 1.07 (0.45–2.53)
P for interaction 0.50 0.50
TSH, mIU/L
0.45–4.49 1762 22 674 1 (Referent) 1 (Referent)
0.10–0.44 41 494 1.31 (0.88–1.95) 1.31 (0.88–1.94)
0.10 16 154 1.94 (1.01–3.72) 1.92 (0.99–3.71)
P for trend 0.047 0.054
Preexisting CVD
None 1091 18 448 33 532 1.50 (0.92–2.44) 1.37 (0.92–2.03)
Yes 669 4214 24 116 1.46 (0.84–2.55) 1.44 (0.83–2.50)
P for interaction 0.94 0.89
Preexisting HF¶
None 1205 10 247 38 273 1.49 (0.87–2.56) 1.47 (0.84–2.59)
Yes 132 440 7 15 1.64 (0.56–4.86) 1.48 (0.45–4.91)
P for interaction 0.88 0.99
HF indicates heart failure; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; and CVD, cardiovascular
disease.
*Adjusted for age, sex, systolic blood pressure, current and former smoking, total cholesterol, and prevalent diabetes mellitus at
baseline.
†These HRs were not adjusted for sex.
‡These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
§Bari was excluded from this stratum because of no participants in the subclinical hyperthyroidism group.
Data on previous CVD were not available for 10 participants in European Prospective Investigation of Cancer (EPIC)–Norfolk and for 2
participants in the Leiden 85-Plus Study.
¶No data were available in EPIC-Norfolk (only preexisting overall CVD assessed); 1 value was missing in Leiden 85-Plus Study. No
participants in Prospective Study of Pravastatin in the Elderly at Risk had preexisting HF, and all participants had HF at baseline in
the Bari study (inclusion criteria).
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these previous studies suggest that clinical thyroid dysfunc-
tion varies over the spectrum of TSH levels and that the risk
of HF was proportional to the degree of TSH elevation and
suppression.
Thyroid hormones play an important function in the
homeostasis of the cardiovascular system with an impact on
cardiac output, cardiac contractility, vascular resistance, and
blood pressure.9 Subclinical hypothyroidism has been asso-
ciated with left ventricular diastolic dysfunction at rest and
during exertion and impaired left ventricular systolic function
on exercise. Higher TSH levels among participants with
subclinical hypothyroidism have been correlated with a de-
creased left ventricular stroke volume, a decrease in cardiac
index, and an increase in systemic vascular resistance.19
Isolated ventricular diastolic dysfunction is associated with
the clinical manifestation of HF33 and might explain the
associated risk of HF events with higher TSH levels in
subclinical hypothyroidism reported in our study. The in-
creased risk of coronary heart disease events with subclinical
hypothyroidism13 might also contribute to the development of
HF because coronary heart disease is a common cause of
HF.34,35 Restoration of a euthyroid state in patients with
subclinical hypothyroidism has been associated with normal-
ization of some structural cardiac parameters,9,36 and 1
randomized controlled trial found that thyroxine therapy in
patients with subclinical hypothyroidism reduced the ratio of
pre-ejection period to left ventricular ejection time,37 but no
large randomized controlled trial of the impact of thyroxine
therapy on HF events has been conducted yet. In contrast to
overt hyperthyroidism, only a few studies reported an effect
of endogenous subclinical hyperthyroidism on cardiac param-
eters: an increased average heart rate, a higher left ventricular
mass, and an impaired diastolic function.20 Two longitudinal
studies reported higher rates of AF with subclinical hyper-
thyroidism,25,38 which might predispose to the development
of HF. Recently, an individual participant analysis has re-
ported an increased risk of AF among participants with
subclinical hyperthyroidism with greater risks in those with
TSH 0.10 mIU/L.12
Among the strengths of our study, our individual partici-
pant data analysis included all available cohorts with data on
subclinical thyroid dysfunction and HF, and this design is
considered the optimal method to perform time-to-event
analyses, to avoid biases associated with subgroups analysis
(ecology fallacy), and to standardize definitions of predictors,
outcomes, and adjustment for potential confounders.13,24,28
Our study had several limitations. First, thyroid function
was measured at baseline, and the possible progression from
subclinical to overt dysfunction was unknown, which is a
limitation of all published observational studies.15,25,27 In
addition, FT3 was measured in only 2 cohorts and thus was
not included in the definition of subclinical hyperthyroidism
in main analyses; sensitivity analyses excluding those with
abnormal FT3 yielded similar results. Second, HF events
were related mainly to hospitalizations, which might lower
the rates of HF events. Because some patients might develop
HF without hospitalization, the rate of recorded HF events is
likely underestimated.15,39 Although we considered a homo-
geneous definition of HF, possible misclassification of HF
events might have occurred because HF is difficult to define
and adjudication might vary across large population studies40;
such misclassification was probably nondifferential because
all HF outcome adjudications were blinded to thyroid status,
and nondifferential misclassification would lower any poten-
tial associations. Even with the large number of individual
participants, some subgroup analyses, particularly among
those 50 years of age and those with preexisting HF, had
limited power because of the limited number of participants
with HF events. We cannot exclude that some interaction or
trend tests might not be significant because of a lack of
power. In particular, a possible effect of sex and race might be
explored in future larger studies. Finally, the studied popula-
tion had limited data on young adults and nonwhite popula-
tions, which limits the generalization of our results to the
entire population.
Conclusions
The combination of all available large prospective cohorts
with 25 378 participants suggests that the risk of HF in-
creased both with lower and higher TSH levels, particularly
in those with TSH levels 10.0 mIU/L and in those with TSH
0.10 mIU/L. For the majority of participants with minimal
TSH disturbances (TSH levels between 4.50 and 6.99 mIU/L
and TSH levels between 0.10 and 0.44 mIU/L), the risk
of HF was not increased compared with euthyroid partic-
ipants. Similar to previous studies,13 we found that subclinical
thyroid dysfunction is a heterogeneous entity with varying
risks of CVD according to TSH levels. The American College
of Cardiology/American Heart Association guidelines for the
diagnosis and management of HF in adults recommend
measuring the thyroid function to investigate conditions that
might exacerbate HF but without specifying the potential
impact of different TSH levels.8 Our findings contribute to a
better interpretation of TSH levels in the prevention and
investigation of HF. Pending results from randomized con-
trolled trials, the findings of our study might be useful to
define the TSH threshold for thyroid medication among
participants with subclinical thyroid dysfunction, although
clinical decisions based only on observational studies should
be made with great caution because they are subject to
limitations. No clinical trial has assessed yet whether treating
subclinical hypothyroidism improved HF outcome. Given the
high prevalence of subclinical hypothyroidism and HF in the
elderly, thyroxine replacement should be investigated with
appropriately powered randomized controlled trials with clin-
ical HF outcomes.
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CLINICAL PERSPECTIVE
Analysis of individual participant data from all available prospective cohorts suggests that the risk of heart failure is
increased with both higher and lower levels of thyroid-stimulating hormone compared with the normal range, particularly
in those with thyroid-stimulating hormone levels 10.0 or 0.10 mIU/L. These findings might lead to a better interpretation of
thyroid-stimulating hormone levels; the latest American College of Cardiology/American Heart Association guidelines for
the diagnosis and management of heart failure in adults recommend measurement of thyroid function to investigate
conditions that might exacerbate heart failure without specifying the clinical impact of different thyroid-stimulating
hormone levels. In the absence of randomized controlled trials that would give definitive evidence about the impact of
treatment on heart failure, our findings might be useful for defining thyroid-stimulating hormone threshold for thyroid
medication, although clinical decisions based only on observational studies should be made with great caution. To
definitively clarify this issue, a randomized controlled trial (Thyroid Hormone Replacement for Subclinical Hypo-
Thyroidism Trial ([TRUST] trial; www.trustthyroidtrial.com) has just been started in Europe among elderly individuals
with subclinical hypothyroidism to assess the impact of thyroxine replacement therapy on cardiovascular outcomes,
including heart failure events.
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Supplemental Methods 
Data Sources and Search Strategies 
We updated the systematic literature search done for our recent analysis on the risks 
associated with subclinical hypothyroidism2, in MEDLINE and EMBASE databases, from 1950 
to June 30, 2011, without language restriction, on the association between subclinical 
thyroid dysfunction and mortality (cardiovascular and total), non-fatal coronary heart 
disease, atrial fibrillation or heart failure. We did our search on an Ovid (MEDLINE) server by 
using broadly defined Medical Subject Headings: thyroid diseases, hypothyroidism, 
hyperthyroidism, thyroid hormones, thyrotropin, heart failure, atrial fribrillation, mortality, 
myocardial ischemia, survival, and cardiovascular diseases; and the following keywords: 
subclinical hypothyroidism, subclinical hyperthyroidism, subclinical dysthyroidism, and 
subclinical thyroid; combined with the filter designed by knowledge information specialists 
from BMJ to select prospective studies (MEDLINE cohort-study filter)3 but without their year 
limitation. We did our search in EMBASE using similar terms. We also searched bibliography 
of key articles and those articles included in this review. 
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Supplemental Table 1. Definitions of Subclinical Thyroid Dysfunction and HF Events 
Abbreviations: HF: Heart Failure; TSH: Thyroid-Stimulating Hormone; T4: Thyroxine; FT4: Free Thyroxine; FT3 Free Triiodothyronine: SA: Sensitivity Analysis 
a fT4 measured only in participants with TSH  7mU/L in this cohort, as overt hypothyroidism is very uncommon in participants with TSH < 7.0 mU/L. 
Study  Subclinical 
hypothyroidism 





TSH ≥4.5 mU/L & TSH 
<20 mU/L, normal FT4 
0.7-1.7 ng/dl (9-22 
pmol/l) or missing FT4 
(21/492, 4.3%) 
TSH < 0.45 mU/L & normal FT4 0.7-
1.7 ng/dl (9-22 pmol/l) or missing 
FT4 (33/43, 76.7%). FT3 value not 
available for SA. 
Based on diagnosis from a physician and 
consideration of symptoms, signs, chest 
radiographs, and treatment of HF 
(current prescription for a diuretic agent 
and digitalis or as vasodilator) 
Based on interview, review of medical records, and 
other support documents. Adjudication by a panel of 
experts without physician knowledge of thyroid status. 
 





TSH ≥4.5 mU/L & TSH 
<20 mU/L, normal FT4 
0.8-1.8 ng/dl (10.3-23.2 




TSH < 0.45 mU/L & normal FT4 0.8-
1.8 ng/dl (10.3-23.2 pmol/l) or 
missing FT4 (57/82, 69.5%)
 a
. FT3 
value not available for SA. 
The HF criteria required at least this 
diagnosis from a physician and treatment 
for HF (current prescription for a diuretic 
agent and either digitalis or a 
vasodilatator) 
Based on symptoms, signs, chest x-ray film results, and 
echocardiography findings. Adjudication by a panel of 
experts without physician knowledge of thyroid status. 
EPIC-Norfolk Study
6
  TSH ≥4.5 mU/L & TSH 
<20 mU/L, normal FT4 
0.7-1.6 ng/dl (9-20 
pmol/L) or missing FT4 
(0/720) 
TSH < 0.45 mU/L & normal FT4 0.7-
1.6 ng/dl (9-20 pmol/L) or missing 
FT4 (0/360). FT3 value not available 
for SA. 
HF events were defined by an 
hospitalization due to HF. 






TSH ≥4.5 mU/L & TSH 
<20 mU/L, normal FT4 
1.0-1.8 ng/dl (13-23 
pmol/L) or missing FT4 
(1/35, 2.9%) 
TSH < 0.45 mU/L & normal FT4 1.0-
1.8 ng/dl (13-23 pmol/L) or missing 
FT4 (0/7), & normal FT3 305-532 
pg/dL (only in SA) 
HF was defined on the basis of a clinical 
diagnosis of acute HF events from a 
physician, who considered symptoms, 
signs, chest radiographs, including 
hospitalisation. 
Annual interview of treating general practitioner and 




 TSH ≥4.5 mU/L & TSH 
<20 mU/L, normal FT4 
0.7-1.8 ng/dl (9-23.2 
pmol/l) or missing FT4 
(0/39) 
TSH <0.45 mU/L & normal FT4 0.7-
1.8 ng/dL (9-23.2 pmol/l) or missing 
FT4 (0/39), & normal FT3 230-420 
pg/dL (only in SA) 
Progression of HF: death, urgent heart 
transplantation or hospitalization due to 
worsening HF.  
Hospital discharge records, ECG, echocardiography 
findings 
Prospective Study of 
Pravastatin in the 
Elderly at Risk 
(PROSPER) ⁹ 
TSH ≥4.5 mU/L & TSH 
<20 mU/L, normal FT4 
0.9-1.4 ng/dl (12-18  
pmol/l) or missing FT4 
(241/444, 54.3%) 
TSH < 0.45 mU/L & normal FT4 0.9-
1.4 ng/dl (12-18   pmol/L) or 
missing FT4 (62/133, 46.6%). FT3 
value not available for SA. 
HF events were defined by an 
hospitalization due to HF. 
A panel of experts adjudicated HF hospitalization, 
based on hospital discharge records, symptoms, signs, 
chest x-ray film results, and echocardiography findings. 
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Supplemental Table 2. Sensitivity analyses of the effect of subclinical hyperthyroidism on the risk of Heart Failure (HF) events 
 
 
Euthyroidism Subclinical Hyperthyroidism 
 
    <0.45 all <0.10 only 
 
Events Participants Events Participants HR (95% CI) Events Participants HR (95% CI) 
All eligible studies 
 





Random-effects model 1762 22,674 57 648 1.46 (0.94, 2.27) 16 154 1.94 (1.01, 3.72) 
Fixed-effects model 1762 22,674 57 648 1.42 (1.09, 1.85) 16 154 2.07 (1.26, 3.41) 
Excluding those with thyroid medication use ¹ 
 





At baseline  1730 22,351 51 589 1.48 (1.02, 2.13) 13 140 1.80 (1.04, 3.13) 
At baseline and during follow-up  1696 22,238 47 576 1.45 (1.00, 2.09) 10 134 1.56 (0.86, 2.82) 







Excluding those with missing FT4  ² 1762 22,674 34 496 1.53 (0.95, 2.48) 15 149 1.89 [1.03, 3.47] 








Three studies with formal adjudication procedures ⁴ 1205 9943 35 258 1.40 (0.69, 2.85) 9 63 1.81 (0.53, 6.24) 







Plus body mass index, creatinin and atrial fibrillation at 
baseline ⁵ 
1326 10,644 45 288 1.60 (0.88, 2.90) 12 73 1.92 (0.63, 5.84) 
Plus lipid-lowering and antihypertensive medications ⁶ 1336 10,681 45 287 1.58 (0.93, 2.70) 12 72 1.92 (0.76, 4.88) 
Excluding study of cardiac patients (Bari) 1709 22,385 54 641 1.38 (0.86, 2.22) 16 154 1.94 (1.01, 3.72) 
Excluding preexisting HF ⁷ 1630 22,234 50 633 1.35 (0.86, 2.12) 13 148 1.64 (0.71-3.80)  
Excluding baseline Atrial Fibrillation ⁸ 1698 22,500 51 635 1.32 (0.86, 2.04) 14 149 1.82 (0.91, 3.63) 
Abbreviations: AF, Atrial Fibrillation; CI,Confidence Interval; FT3, Free tri-iodothyronine; FT4, Free thyroxine; HF, Heart Failure; HR, Hazard Ratio; NA, data not applicable; TSH, Thyroid Stimulatiing 
Hormone. HR are all age and sex-adjusted unless stated otherwise 
¹ The numbers of participants with thyroid medication appear in Table 1. 
² 152 participants with subclinical hyperthyroidism and missing T4 were excluded : 33 excluded from CHS, 57 from Health ABC and 62 from PROSPER, 
³ 21 participants with subclinical hyperthyroidism and abnormal T3 were excluded : Leiden 21, Bari 0 (not  measured in other studies). 
⁴ Formal adjudication procedures with experts adjudicating each case were performed only in CHS, Health ABC and PROSPER. Other cohorts relied on hospital discharge and General Practitioner's 
medical records. 
⁵ Data on creatinine and atrial fibrillation were not available for the EPIC-Norfolk study. 44 participants with missing data: 6 in CHS, 23 in Health ABC and 15 in Leiden 
⁶ Data on lipid-lowering and antihypertensive medications were not available for the EPIC-Norfolk study. 8 participants with missing data in Health ABC. 
⁷ 455 excluded because of HF at baseline: 9 in CHS, 95 in Health ABC, 55 in Leiden, 296 in Bari (all participants with preexisting HF), 0 in PROSPER.  Data on preexisting HF were not available for EPIC 
study (only preexisting overall CVD assessed); after excluding those with preexisting CVD from EPIC, HR was 1.43 (0.59, 3.48) for TSH < 0.10 mIU/L 
⁸ 187 participants were excluded because of AF at baseline: 50 in CHS, 48 in Health ABC, 49 in Leiden and 36 in Bari. Data were not available for EPIC-Norfolk study. Baseline AF was an exclusion 
criteria from PROSPER study (4 participants had AF at baseline). 1 missing in HABC, 2 missing in Leiden.  Prevalence of baseline AF across TSH ranges: 170/5615 (3.0%) for TSH 0.45-4.49 mIU/L, 8/115 
(7.0%) for TSH 0.10-0.44 mIU/L and 5/40 (12.5%) for TSH <0.10 mIU/L.  




Records identified through 
database searching 
(n = 5410) 
Additional records identified 
from reference lists & experts 
(n = 3) 
Records after duplicates 
removed 
(n = 5277) 
 
Records excluded based on title and abstract 
(unrelated to the association between 
subclinical thyroid dysfunction and HF events) 
(n = 5211) 
Full-text articles excluded (n = 60) due to 
 No specific data on subclinical 
hypothyroidism (n = 13) 
 No prospective data on outcomes (n = 26) 
 No numeric data on outcomes (n = 2) 
 Reported the same study already selected 
without additional data to extract (n = 4) 
 Review article, meeting abstract or editorial 
(n = 8) 
 All patients treated for thyroid dysfunction 
(n = 3) 
 No T4 measurement (n = 4) 
Records screened 
(n = 5277) 
 
Full-text articles assessed 
for eligibility 
(n = 66) 
Studies meeting inclusion 
criteria 
(n = 6) 
Studies included in 
quantitative synthesis 
(IPD analysis) 
(n = 6) 
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Supplemental Figure Legends 
 
 
Supplemental Figure 1. Flow Chart: Studies Evaluated for Inclusion in the Individual 
Participant Data Analysis for the association between Subclinical Thyroid Dysfunction and 
Heart Failure events, Adapted from PRISMA Statement Flow Diagram1    (Page R5) 
 
Supplemental Figure 2. Forest plots of Heart Failure (HF) events in Subclinical 
Hypothyroidism vs. Euthyrodism  (Page R6) 
 
Abbreviations: CI: Confidence Interval; HR: Hazard Ratio  
Age- and gender-adjusted HRs and their 95% CI are represented by squares. Squares to the 
right of the solid lines indicate increased risk of HF events.  
Supplemental Figure 3. Forest plots of Heart Failure (HF) and in Subclinical Hyperthyroidism 
vs. Euthyroidism  (Page R7) 
 
Abbreviations: CI: Confidence Interval; HR: Hazard Ratio 
Age- and gender-adjusted HRs and their 95% CI are represented by squares. Squares to the 
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